NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neogen Corporation (NASDAQ: NEOG) between January 5, 2023 and June 3, 2025, inclusive (the “Class Period”), of the important September 16, 2025 lead plaintiff deadline. SO WHAT: If you purchased Neogen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

Group 1 - The Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Capricor Therapeutics, Inc. securities between October 9, 2024, and July 10, 2025 [1] - Investors who purchased Capricor securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A lead plaintiff must move the Court by September 15, 2025, to represent other class members in the litigation [3] Group 2 - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, while concealing adverse facts about its safety and efficacy data from a Phase 2 trial [5] - The misleading statements led to shareholders purchasing Capricor's securities at artificially inflated prices, resulting in damages when the true information was revealed [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased iRobot Corporation securities between January 29, 2024, and March 11, 2025, about the September 5, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought iRobot securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by September 5, 2025, to serve as lead plaintiff [2]. - The lawsuit alleges that iRobot made false and misleading statements regarding its Restructuring Plan and its ability to operate profitably as a standalone company after the termination of the Amazon Acquisition [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Rosen Law Firm has been recognized as a leader in securities class action settlements, being ranked No. 1 in 2017 and consistently in the top 4 since 2013 [3].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Vera Bradley, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Vera Bradley securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Financial Performance and Market Reaction - On June 11, 2025, Vera Bradley announced disappointing financial results for the first quarter of the 2026 fiscal year, leading to a 19% drop in stock price on the same day [3]. - The CEO of Vera Bradley acknowledged that top line and profitability trends had continued to decline over several quarters [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm or visiting their website [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by August 11, 2025, acting on behalf of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for the number of securities class action settlements since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that Rocket Pharmaceuticals made misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing serious adverse events, including participant deaths [5]. - It is claimed that these misleading statements led to artificially inflated prices for Rocket Pharmaceuticals securities, resulting in investor damages when the true information became public [5].

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1 trial Data will include patients from the dose escalation and at multiple expansion doses U.S. Phase 1 trial of IDE849 in SCLC patients initiated in 3Q 2025JIANGSU, China and SOUTH SAN FRANCISCO, Calif., July 22, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Jiangsu Hengrui Pharmaceutic ...

Group 1 - The Rosen Law Firm is reminding investors who purchased 3D Systems Corporation securities between August 13, 2024, and May 12, 2025, of the August 12, 2025, lead plaintiff deadline for a class action lawsuit [1][2] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [2][5] Group 2 - The lawsuit alleges that during the class period, 3D Systems made false and misleading statements regarding its business resilience and the impact of weakened customer spending [4] - It is claimed that the updated milestone criteria in a partnership with United Therapeutics Corporation would negatively affect 3D Systems' Regenerative Medicine Program revenue [4] - The lawsuit asserts that these misleading public statements resulted in investor damages when the true information became public [4] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [3] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise in this area [3]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Biohaven Ltd. securities, alleging misleading statements regarding the company's drug regulatory prospects and clinical efficacy during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Biohaven Ltd. securities purchased between March 24, 2023, and May 14, 2025 [1]. - Allegations include that Biohaven overstated the regulatory prospects of its drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, which could negatively impact the company's business and financial condition [5]. Group 2: Participation Information - Investors who purchased Biohaven securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Centene Corporation securities during the specified Class Period, indicating potential legal issues for the company related to misleading statements about its financial performance [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for investors who purchased Centene common stock between December 12, 2024, and June 30, 2025, and aims to provide compensation without out-of-pocket fees through a contingency fee arrangement [2][5]. - The lawsuit alleges that Centene's management provided materially false and misleading information regarding the company's expected revenue guidance and adjusted diluted earnings per share (EPS) for the 2025 fiscal year, while concealing adverse facts about enrollment and morbidity rates [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions, highlighting the Rosen Law Firm's achievements in this area, including significant settlements and recognition in the legal community [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone, showcasing its capability in handling such cases [4]. Group 3: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly for more information [3][6]. - It is noted that no class has been certified yet, meaning investors are not represented unless they retain counsel, and participation as a lead plaintiff is not necessary for potential recovery [7].

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased PepGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NE ...